Company: BLRX
Filing Date: 2025-01-07
Form Type: 6-K
Source: 0001178913-25-000047
Chunk: 2

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 6-K
Chunk 2
---
 the sale of the ADSs in the Offering, a non-accountable expense allowance of $25,000, $40,000 for accountable expenses and clearing fees of $15,950. The Placement Agent or its designees will also receive warrants (the “Placement Agent Warrants”) on substantially the same terms as the investors in the Offering in an amount equal to 5% of the aggregate number of ADSs sold in the Offering, or 2,500,000 ADSs, at an exercise price of $0.25 per ADS and expiration date of January 6, 2030. The securities described above and to be issued in the Offering are being issued pursuant to a prospectus supplement dated as of January 6, 2025, which will be filed with the Securities and Exchange Commission, in connection with a takedown from the Company’s shelf registration statement on Form F-3 (File No. 333-276323) (the “Registration Statement”), which became effective on January 5, 2024, and the base prospectus dated as of January 5, 2024 contained in such Registration Statement. This Report on Form 6-K shall not constitute an offer to sell or the solicitation to buy, nor shall there be any sale of, any of the securities described herein in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The foregoing descriptions of the Purchase Agreement, the Pre-Funded Warrants and the Ordinary Warrants are not complete and are qualified in their entirety by reference to the full text of such documents, copies of which are filed as exhibits to this Report on Form 6-K and are incorporated by reference herein. A copy of the opinions of FISCHER (FBC & Co.) and Greenberg Traurig, P.A. relating to the legality of the securities are attached as Exhibit 5.1 and Exhibit 5.2 hereto, respectively. The Company previously announced the Offering in a press release issued on January 6, 2025, which was included as an exhibit to a Report on Form 6-K filed with the SEC on the same day. This Report on Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Forward Looking Statements This Report of on Form 6-K contains statements which constitute forward looking statements within the meaning